Floatz Rating
B60/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03439085CT.gov DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | — | Terminated | — | — | — |
NCT03277482CT.gov Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vaginal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | M.D. Anderson Cancer Center | P2 | B · 60 |
| Plasmid Encoded Il-12 | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457 | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Dehydroepiandrosterone | Ohio State University Comprehensive Cancer Center | P2 | CCC |
| Carboplatin | Case Comprehensive Cancer Center | P1 | CCC |
| Trastuzumab | National Cancer Institute (NCI) | P1 | CC |
| Recombinant Interleukin-12 | National Cancer Institute (NCI) | P1 | CC |
+10 more in the Vaginal Carcinoma cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Plasmid Encoded Il-12M.D. Anderson Cancer CenterCCC
- IpilimumabNational Cancer Institute (NCI)CCC
- Dna Plasmid-Encoding Interleukin-12/Hpv Dna Plasmids Therapeutic Vaccine Medi0457M.D. Anderson Cancer CenterCCC
- NivolumabNational Cancer Institute (NCI)CCC
- DehydroepiandrosteroneOhio State University Comprehensive Cancer CenterCCC
Citation
Floatz Terminal. Durvalumab in Vaginal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-vaginal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →